List of Spiriva drug patents

Spiriva is owned by Boehringer Ingelheim.

Spiriva contains Tiotropium Bromide.

Spiriva has a total of 12 drug patents out of which 7 drug patents have expired.

Expired drug patents of Spiriva are:

  • US7070800
  • US6908928*PED
  • US7642268*PED
  • US7309707*PED
  • US6777423*PED
  • USRE38912*PED
  • US7070800*PED

Spiriva was authorised for market use on 30 January, 2004.

Spiriva is available in powder;inhalation dosage forms.

Spiriva can be used as administration of an inhalable powder comprising tiotropium via device, for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.

The generics of Spiriva are possible to be released after 19 April, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070800 BOEHRINGER INGELHEIM Inhalable powder containing tiotropium
Jan, 2022

(1 year, 6 days ago)

US6908928

(Pediatric)

BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Mar, 2022

(10 months ago)

US7642268

(Pediatric)

BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Mar, 2022

(10 months ago)

US7309707

(Pediatric)

BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Mar, 2022

(10 months ago)

US6777423

(Pediatric)

BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Mar, 2022

(10 months ago)

USRE38912

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing powder formulations
Apr, 2022

(9 months ago)

US7070800

(Pediatric)

BOEHRINGER INGELHEIM Inhalable powder containing tiotropium
Jul, 2022

(6 months ago)

US8022082 BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation
Jan, 2026

(2 years from now)

US8022082

(Pediatric)

BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation
Jul, 2026

(3 years from now)

US7694676 BOEHRINGER INGELHEIM Dry powder inhaler
Mar, 2027

(4 years from now)

US7694676

(Pediatric)

BOEHRINGER INGELHEIM Dry powder inhaler
Sep, 2027

(4 years from now)

US9010323 BOEHRINGER INGELHEIM Inhaler and sieve for an inhaler
Apr, 2030

(7 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 30 January, 2004

Treatment: For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Administration of an inhalable powder comprising tiotropium via device

Dosage: POWDER;INHALATION

How can I launch a generic of SPIRIVA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic